Renal protective potential of antihypertensive drugs

Expert Opinion on Investigational Drugs

Volumn 9, Issue 11, 2000, Pages 2593-2600

  Susic, D ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

Antihypertensive drugs; Diabetes mellitus; End stage renal disease; Hypertension; Renoprotection

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARVEDILOL; COLLAGEN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; ENZYME INHIBITOR; FELODIPINE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; NIFEDIPINE; PEPTIDASE; PLATELET DERIVED GROWTH FACTOR; PROPRANOLOL; QUINAPRIL; RAMIPRIL; RENIN; SOMATOMEDIN; THROMBOXANE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; VASOACTIVE AGENT; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENCY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; NONHUMAN; RAT; RENAL ARTERY; REVIEW;

EID: 0033766777     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.11.2593     Document Type: Review

References (59)

1. Incidence and prevalence of ESRD
2. End-stage renal failure in Type 2 diabetes: A medical catastrophe of worldwide dimensions
3. Nephroprotective effect of antihypertensive drugs in essential hypertension
4. Diabetes and hypertension: Blood pressure control and consequences
5. Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model
6. Blood pressure and end-stage renal disease in men
7. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy
8. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
9. Effects of ramipril on cardiovascular and micovascular outcomes in people with diabetes mellitus: Results of the HOPE and MICROHOPE study
10. Coronary hemodynamics in aging spontaneously hypertensive and normotensive Wistar-Kyoto rats
11. Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats
12. Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive and normal rats
13. The role of nephron mass and of intraglomerular pressure in initiation and progression of experimental hypertensive-renal disorders
14. Monitoring diabetic nephropathy: Glomerular filtration rate and abnormal albuminuria in diabetic renal disease-reproducibility, progression, and efficacy of antihypertensive intervention
15. Glomerular hyperfiltration in microalbuminuric NIDDM patients
16. A short-term antihypertensive treatment induced fall in glomerular filtration rate predicts long-term stability of renal function
17. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy
18. Endothelial function and the kidney. An emerging target for cardiovascular therapy
19. Pathogenesis, prevention and treatment of diabetic nephropathy
20. Molecular mechanisms of diabetic renal hypertrophy
21. Increased expression of TGF-β1 mRNA in obstructed kidney of rats with unilateral ureteral obstruction
22. Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy
23. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with receptor antagonist
24. Captopril-induced reduction of serum levels of transforming growth factor-β1 correlates with long-term nephroprotection in insulin-dependent diabetic patients
25. The extracellular matrix in diabetic nephropathy
26. Link between angiotensin II and TGF-β in the kidney
27. Vascular hypertrophy in experimental diabetes: Role of advanced glycation end products
28. Expression of transforming growth factor-β1 and Type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of angiotensin converting enzyme inhibition
29. Understanding the nature of renal disease progression
30. Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications
31. Pathophysiology of progressive nephropathies
32. Should we screen for microalbuminuria in essential hypertension
33. ACE inhibition induces regression of proteinuria and halts progression of renal damage in genetic model of progressive nephropathy
34. Effect of ACE inhibition on glomerular basement membrane permeability and distribution of ZO-1 in MWF rats
35. Carvedilol: A beta blocker with antioxidant property protects against gentamicin-induced nephrotoxicity in rats
36. Carvedilol protects against glomerulosclerosis in the rat remnant kidney model without general changes in antioxidant enzyme status. A comparative study of two beta-blocking drugs, carvedilol and propranolol
37. Preservation of renal function; the spectrum of effects of calcium channel blockers
38. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidney
39. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists
40. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms
41. Renoprotective effect of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME
42. Antiproteinuric efficacy of verapamil in comparison with to trandolapril in non-diabetic renal disease
43. Effects of blood pressure control on progressive renal disease in blacks and whites
44. Differences between nisoldipine and lisinopril in GFRs and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment
45. Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy
46. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system
47. Emerging treatments for hypertension: Potential role for vasopeptidase inhibition
48. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes
49. Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats
50. Protective effects of endothelin antagonists in chronic renal failure
51. An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis
52. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
53. Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: Either or both for primary renal disease
54. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
55. Safety of the combination of valsartan and benazepril in patients with chronic renal disease
56. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy
57. Endothelin-A receptor antagonist combined with hydralazine improves survival and renal function in hypertensive rats
58. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding
59. Breakers of advanced glycation end products restore large artery properties in experimental diabetes